Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients
- PMID: 8779128
- PMCID: PMC1090636
- DOI: 10.1136/thx.51.3.262
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients
Abstract
Background: A study was performed to compare the adrenal suppression caused by inhaled fluticasone propionate and budesonide on a microgram equivalent basis, each given by metered dose inhaler to asthmatic patients.
Methods: Twelve asthmatic patients of mean age 29.9 years, with a forced expiratory volume in one second (FEV1) 92.9% predicted and forced expiratory flow 25-75% (FEF25-75) 69.5% predicted, on less than or equal to 400 micrograms/day inhaled corticosteroid, were studied in a double blind placebo controlled crossover design comparing single doses of inhaled budesonide 400, 1000, 1600, 2000 micrograms and fluticasone propionate 500, 1000, 1500, 2000 micrograms. Doses were administered at 22.00 hours by metered dose inhaler with mouth rinsing and measurements were made in the laboratory 10 hours later.
Results: Serum cortisol levels compared with placebo (mean 325.2 nmol/l) were suppressed by fluticasone at doses of 1500 micrograms (211.6 nmol/l) and 2000 micrograms (112.3 nmol/l) and by budesonide at 2000 micrograms (243.4 nmol/l). Fluticasone propionate 2000 micrograms produced lower absolute serum cortisol levels than budesonide 2000 micrograms (95% CI for difference 42.9 to 219.2). The dose ratio (geometric mean) for the relative potency was 2.89 fold (95% CI 1.19 to 7.07). In terms of percentage suppression versus placebo, fluticasone propionate also produced greater effects (means and 95% CI for difference): budesonide 1600 micrograms (16.0) versus fluticasone propionate 1500 micrograms (40.9) (95% CI -0.6 to 50.6), budesonide 2000 micrograms (26.0) versus fluticasone 2000 micrograms (65.2) (95% CI 10.5 to 67.8). Individual serum cortisol levels at the two highest doses showed 15 of 24 patients below the normal limit of the reference range (150 nmol/l) for fluticasone and five of 24 for budesonide. Fluticasone propionate also caused greater ACTH suppression than budesonide (as % versus placebo): budesonide 1600 micrograms (12.0) versus fluticasone propionate 1500 micrograms (31.9) (95% CI 7.6 to 32.1), budesonide 2000 micrograms (13.5) versus fluticasone propionate 2000 micrograms (44.4) (95% CI 13.2 to 48.7). For overnight 10 hour urinary cortisol (nmol/10 hours) there was a difference between the lowest doses of the two drugs: budesonide 400 micrograms (37.2) versus fluticasone propionate 500 micrograms (19.9) (95% CI 6.9 to 27.8).
Conclusions: Like budesonide the systemic bioactivity of fluticasone propionate is mainly due to lung vascular absorption. Fluticasone propionate exhibited at least twofold greater adrenal suppression than budesonide on a microgram equivalent basis in asthmatic patients.
Similar articles
-
Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients.Thorax. 1997 Jan;52(1):55-8. doi: 10.1136/thx.52.1.55. Thorax. 1997. PMID: 9039246 Free PMC article. Clinical Trial.
-
Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children.Thorax. 1996 Sep;51(9):941-3. doi: 10.1136/thx.51.9.941. Thorax. 1996. PMID: 8984708 Free PMC article. Clinical Trial.
-
Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children.Thorax. 1997 Aug;52(8):686-9. doi: 10.1136/thx.52.8.686. Thorax. 1997. PMID: 9337826 Free PMC article. Clinical Trial.
-
Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.Drugs. 2000 Nov;60(5):1207-33. doi: 10.2165/00003495-200060050-00012. Drugs. 2000. PMID: 11129128 Review.
-
Salmeterol/fluticasone propionate combination.Drugs. 1999 Jun;57(6):933-40; discussion 941-3. doi: 10.2165/00003495-199957060-00010. Drugs. 1999. PMID: 10400406 Review.
Cited by
-
A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.J Pharmacokinet Biopharm. 1999 Apr;27(2):127-47. doi: 10.1023/a:1020670421957. J Pharmacokinet Biopharm. 1999. PMID: 10567952
-
Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients.Thorax. 1997 Jan;52(1):55-8. doi: 10.1136/thx.52.1.55. Thorax. 1997. PMID: 9039246 Free PMC article. Clinical Trial.
-
Hospitalized patients with COPD: analysis of prior treatment.J Bras Pneumol. 2014 May-Jun;40(3):229-37. doi: 10.1590/s1806-37132014000300005. J Bras Pneumol. 2014. PMID: 25029645 Free PMC article.
-
Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5. Clin Respir J. 2013. PMID: 23578031 Free PMC article. Clinical Trial.
-
Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.Eur J Clin Pharmacol. 2009 Sep;65(9):853-71. doi: 10.1007/s00228-009-0682-z. Epub 2009 Jun 26. Eur J Clin Pharmacol. 2009. PMID: 19557399 Review.